UK-based Summit Therapeutics (NASDAQ:SMMT) has a bit of good news for Duchenne muscular dystrophy (DMD) investors who are about to bloodied today if they are holding shares in Sarepta Therapeutics (NASDAQ:SRPT). The FDA has cleared its Investigational New Drug (IND) application for DMD candidate ezutromid (formerly SMT C1100) which clears the way to recruit U.S. trial sites in its Phase 2 proof-of-concept study called PhaseOut DMD. The 48-week open-label study, initiated in the UK in January… Read More
Agree AMM, Hopefully they'll finally have all their ducks lined up to start the PhaseOut UK trial next week. I got the impression from the last interview it's been hard work to get the three test centres lined up together.
Also the discussions on the C.Diff partnering deal must be well progressed now. Although it's only May next week and I expected them to take until at least June to finalise a deal. Maybe they'll surprise us. I wouldn't have thought either side would want to delay... the… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.